INDEPENDENT VERDICT
Sage Partners Alpha 1 L.P. is unusual because its September 2026 Form D amendment is important for what did not change. The Cayman partnership still reports $56.03 million sold in an indefinite Rule 506(b) offering with a $500,000 minimum and 20 cumulative investors. SEC history shows the fund began with approximately $3 million reported in its 2021 filing, then increased by roughly $53.03 million in 2022 to reach the current $56.03 million level; later 2023, 2024 and 2026 amendments did not add further reported offering sales. That makes Alpha 1 fundamentally different from a newly fundraising fund. It appears to be a mature vehicle whose U.S. Regulation D capital base has remained stable while the wider Sage Partners platform continued operating and raising or managing capital through other entities. The filing identifies Sage Partners Private Fund as General Partner, Wang Fei, Yolanda Banks McCoy and Christopher Alan Day as directors of that GP, and Sage Partners Limited as the investment manager. SEC records therefore establish the legal chain clearly, but the $56.03 million figure should not be interpreted as the total size of Sage Partners' investment platform.
THE BIGGER STORY IS THAT ALPHA 1 SITS BESIDE OTHER SAGE VEHICLES WITH VERY DIFFERENT CAPITAL FIGURES
Sage Partners Onshore Fund provides the clearest comparison. Its March 24, 2026 Form D/A reported $152.75 million sold to 15 investors, a $500,000 minimum and an April 15, 2020 first sale. Like Alpha 1, the Onshore Fund identifies Sage Partners Limited as investment manager and uses the same Hong Kong AIA Tower management address. Yet the legal forms differ: Alpha 1 is a Cayman exempted limited partnership, while the Onshore Fund is a Cayman exempted company. Sage Partners Offshore Fund and Sage Partners Master Fund also appear in the broader platform. Those entities should not be added mechanically: a feeder, onshore sleeve, offshore sleeve or master fund can hold overlapping economic capital. The public evidence establishes a multi-vehicle architecture, but the reviewed Form D filings do not provide enough detail to calculate consolidated platform NAV without risking double counting.
SAGE PARTNERS IS NOT JUST A FORM D NAME — THE HONG KONG REGULATORY AND IPO RECORDS IDENTIFY THE ACTUAL INVESTMENT BUSINESS
Sage Partners Limited is independently documented by Hong Kong regulators as a licensed corporation with SFC CE number BOT987 and Type 9 Asset Management permission, with the license dating to March 31, 2020. Hong Kong Stock Exchange prospectuses repeatedly describe Sage Partners Limited as the investment manager of Sage Partners vehicles and identify Wang Fei as the controlling individual behind the manager. Those documents also describe a consistent investment philosophy: long-term fundamental investing focused historically on healthcare, with later disclosures expanding the description to healthcare and emerging technologies. This evidence is particularly valuable because FilingDossier did not locate a clearly attributable official public website for this specific licensed manager. A separate site using the Sage Partners name describes a multi-family office active in real estate and private equity, but its branding, business description and personnel evidence are insufficient to link it to Sage Partners Limited BOT987. It should therefore not be used as the manager's official website.
THE MASTER FUND HAS A PUBLIC TRANSACTION TRAIL THAT MAKES THE STRATEGY MORE CONCRETE
Unlike many Cayman hedge funds whose portfolio remains almost entirely private, Sage Partners Master Fund appears repeatedly in Hong Kong listing documents as an institutional or cornerstone investor. A 2021 prospectus described the Master Fund as investing primarily in pharmaceutical and healthcare-related companies. More recent Hong Kong offering documents describe the strategy as healthcare plus emerging technologies. In 2025, a listed-company allocation document showed Sage Partners Master Fund holding 897,100 H shares in one issuer subject to post-listing lock-up arrangements. In 2026, another Hong Kong IPO document disclosed a cornerstone investment agreement under which Sage Partners Master Fund subscribed for the Hong Kong-dollar equivalent of US$4 million of H shares. Separately, an April 2026 investor-relations record from Micro-Tech (Nanjing) lists Sage Partners Limited among institutional participants at a company results meeting. None of these transactions proves that Alpha 1 directly owns the securities, because the named investor is the Master Fund or the manager rather than Alpha 1 itself. But together they provide stronger evidence of the platform's actual healthcare/emerging-technology investment activity than generic marketing language.
THE INVESTOR COUNT ALSO NEEDS TO BE READ DIFFERENTLY FROM THE CAPITAL NUMBER
Alpha 1's 2026 amendment reports 20 cumulative investors and explicitly notes that the investor count is cumulative since fund inception. That disclosure matters because investor count can change even when cumulative Form D securities sold remain unchanged. A redemption, transfer, feeder subscription or investor-class change does not necessarily produce a new "amount sold" in the way a new subscription does. The combination of stable $56.03 million reported sales and 20 cumulative investors therefore should not be used to infer current NAV, current investor ownership percentages or current cash in the fund. Similarly, the Onshore Fund's $152.75 million Form D amount represents securities sold under that issuer's exempt offering, not necessarily current NAV after gains, losses, withdrawals or cross-vehicle investments.
FINAL ASSESSMENT
Sage Partners Alpha 1 has a research story that is unusually well supported outside the SEC database. Five entity-specific facts define it: the fund's reported sales rose from roughly $3 million in 2021 to $56.03 million in 2022 and have remained at that level through the September 2026 amendment; its investment manager is Hong Kong SFC Type 9 licensee Sage Partners Limited, CE BOT987; Wang Fei is repeatedly identified in both SEC and Hong Kong listing documents as a central manager/GP figure; a separate Sage Partners Onshore Fund reports $152.75 million of securities sold; and the broader Master Fund has appeared as an actual institutional investor in healthcare and emerging-technology transactions, including a disclosed US$4 million 2026 cornerstone subscription. The main diligence challenge is therefore not proving that the manager exists. It is understanding how Alpha 1, Onshore, Offshore and Master Fund capital flows interact, which assets belong economically to each vehicle, and whether published Master Fund investments should be attributed proportionally to Alpha 1 investors.
SEC SNAPSHOT
Issuer: Sage Partners Alpha 1 L.P. CIK: 0001887191 SEC Form: Form D/A Accession No.: 0001887191-26-000001 Latest Filing Date: September 14, 2026 Year Organized: 2020 Jurisdiction: Cayman Islands Entity Type: Exempted Limited Partnership Principal Address: Ugland House, 121 South Church Street, Grand Cayman, Cayman Islands KY1-1104 Telephone: +852 3992 1370 Industry: Pooled Investment Fund Fund Classification: Hedge Fund Investment Company Registered: No Investment Company Act Exclusions: Sections 3(c)(1) and 3(c)(7) Offering Exemption: Rule 506(b) Security Types: Equity / Pooled Investment Fund Interests Offering Amount: Indefinite Amount Sold: $56,030,000 Investors: 20 cumulative Minimum Investment: $500,000 First Sale: June 2, 2021 Offering Duration Over One Year: Yes Sales Commissions: $0 Finder's Fees: $0 Estimated Related-Person Proceeds: $0 General Partner: Sage Partners Private Fund Investment Manager: Sage Partners Limited Named GP Director: Wang Fei Named GP Director: Yolanda Banks McCoy Named GP Director: Christopher Alan Day Signer: Tan Qiaowei Signer Role: Authorised Signatory of the Investment Manager
FILING HISTORY
2021 Initial Reported Amount Sold: Approximately $3,000,000 2022 Incremental Increase: Approximately $53,030,000 2022 Cumulative Amount Sold: $56,030,000 2023 Amendment: No additional reported sales 2024 Amendment: No additional reported sales 2026 Amendment: $56,030,000 cumulative 2026 Investors: 20 Interpretation: Form D fundraising total has remained stable after the major 2022 increase
SAGE FUND ARCHITECTURE
Sage Partners Alpha 1 L.P.: Confirmed Sage Partners Onshore Fund: Confirmed Sage Partners Offshore Fund: Confirmed Sage Partners Master Fund: Confirmed in Hong Kong public transaction documents General Partner of Alpha 1: Sage Partners Private Fund Investment Manager Across Relevant Vehicles: Sage Partners Limited Onshore Fund March 2026 Amount Sold: $152,750,000 Onshore Fund Investors: 15 Onshore Fund Minimum Investment: $500,000 Onshore First Sale: April 15, 2020 Alpha 1 and Onshore amounts proven fully additive: NO Alpha 1 proven feeder to Master Fund in reviewed Form D: NO Onshore proven feeder to Master Fund in reviewed Form D: NO Master / feeder economic allocation publicly quantified: NO
WEBSITE / ENTITY PENETRATION
Sage Partners Alpha 1 SEC issuer confirmed: YES Sage Partners Private Fund GP relationship confirmed: YES Sage Partners Limited investment-manager relationship confirmed: YES Wang Fei relationship confirmed by SEC: YES Wang Fei relationship confirmed by Hong Kong public transaction documents: YES Yolanda Banks McCoy GP-director relationship confirmed: YES Christopher Alan Day GP-director relationship confirmed: YES Sage Partners Limited Hong Kong SFC license confirmed: YES SFC CE Number: BOT987 SFC Regulated Activity: Type 9 Asset Management SFC license addition dated March 31, 2020: YES Hong Kong management address: Room 4331, Level 43, AIA Tower, 183 Electric Road, North Point Current SEC related-person address matches Hong Kong management address: YES Dedicated official website for Sage Partners Limited BOT987 independently confirmed: NO sagepartners.io proven to be Sage Partners Limited BOT987: NO Sage Partners Master Fund healthcare investment focus documented: YES Emerging-technology focus documented in later offering materials: YES Public cornerstone-investment activity documented: YES
PUBLIC INVESTMENT EVIDENCE
Sage Partners Master Fund identified in Hong Kong listing documents: YES Healthcare focus documented historically: YES Emerging technology focus documented more recently: YES 2025 listed-company H-share holding disclosed: YES Number of H Shares in cited 2025 disclosure: 897,100 2026 cornerstone investment disclosed: YES 2026 Cornerstone Subscription: Hong Kong-dollar equivalent of US$4,000,000 Sage Partners Limited attendance at Micro-Tech 2026 investor meeting: YES Evidence these securities belong directly to Alpha 1 rather than Master Fund: NO
CORE INVESTOR QUESTIONS
Does Alpha 1 invest directly into Sage Partners Master Fund What percentage of Master Fund ownership is attributable to Alpha 1 How does Sage Partners Onshore Fund relate economically to Alpha 1 How does Sage Partners Offshore Fund relate to the Master Fund Would adding the $56.03 million Alpha 1 figure to the $152.75 million Onshore figure double count underlying capital Why has Alpha 1 reported no additional cumulative securities sales since 2022 What is Alpha 1's current NAV versus its historical Form D amount sold How much capital has been redeemed since inception Which healthcare and emerging-technology positions are currently held by the Master Fund Does Alpha 1 participate proportionally in the Master Fund's Hong Kong cornerstone investments What management and performance fees apply What are the fund's net returns since the June 2021 first sale What is the largest portfolio concentration How much exposure is in public equities versus private/pre-IPO investments What liquidity and redemption restrictions apply Who currently serves as auditor, administrator, prime broker and custodian How are private or pre-IPO holdings valued What conflicts exist when multiple Sage vehicles invest in the same security
PRIMARY EVIDENCE REVIEWED
SEC Form D/A for Sage Partners Alpha 1 L.P. filed September 14, 2026. Historical SEC Form D filings for Sage Partners Alpha 1 from 2021 through 2024. SEC Form D/A for Sage Partners Onshore Fund filed March 24, 2026. SEC filings for Sage Partners Offshore Fund. Hong Kong Securities and Futures Commission licensing record identifying Sage Partners Limited, CE BOT987, for Type 9 Asset Management. Hong Kong Stock Exchange prospectuses identifying Sage Partners Limited as investment manager and describing Sage Partners' healthcare and emerging-technology strategy. Hong Kong listing records identifying Sage Partners Master Fund as an investor. 2026 Hong Kong cornerstone investment agreement involving Sage Partners Master Fund. 2026 Micro-Tech investor-relations record listing Sage Partners Limited among institutional participants. Public website searches used to test whether sagepartners.io belongs to this manager; relationship not confirmed.
IMPORTANT FORM D NOTICE
Sage Partners Alpha 1's $56.03 million Form D amount sold is a cumulative exempt-offering figure and is not necessarily the fund's current NAV. Sage Partners Onshore Fund's $152.75 million sold amount is a separate issuer-level figure and should not automatically be added to Alpha 1 because public records reviewed do not establish whether the vehicles feed a common master portfolio or otherwise contain overlapping economic capital. Sage Partners Limited's SFC Type 9 license confirms its Hong Kong asset-management regulatory status; it is not an endorsement of Alpha 1, its investments or performance.